InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,306.80
(
0.48%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.42
(
1.12%
)
Bitcoin
61,567.60
(
1.24%
)
Post# of 252412
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: iandy post# 151271

Friday, 10/26/2012 9:47:34 AM

Friday, October 26, 2012 9:47:34 AM

Post# of 252412
Look, Sprycel and Tasigna already have data stronger than Gleevec in newly diagnosed CML, but Gleevec still dominates in that market. Why do you think it will be different for ponatinib especially after Gleevec becomes generic?
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up